Parkinson�s disease (PD) was characterized by late-onset, progressive dopamine neuron\nloss and movement disorders. The progresses of PD affected the neural function and\nintegrity. To date, most researches had largely addressed the dopamine replacement\ntherapies, but the appearance of L-dopa-induced dyskinesia hampered the use of the\ndrug. And the mechanism of PD is so complicated that it�s hard to solve the problem by\njust add drugs. Researchers began to focus on the genetic underpinnings of Parkinson�s\ndisease, searching for new method that may affect the neurodegeneration processes in\nit. In this paper, we reviewed current delivery methods used in gene therapies for PD,\nwe also summarized the primary target of the gene therapy in the treatment of PD, such\nlike neurotrophic factor (for regeneration), the synthesis of neurotransmitter (for prolong\nthe duration of L-dopa), and the potential proteins that might be a target to modulate\nvia gene therapy. Finally, we discussed RNA interference therapies used in Parkinson�s\ndisease, it might act as a new class of drug.We mainly focus on the efficiency and tooling\nfeatures of different gene therapies in the treatment of PD.
Loading....